Biotechnology

Beijing is pouring trillions into AI, 6G, and biomanufacturing to dominate the next tech era, offering Europe partnership amidst rising competition.

Early access programs for a rare blindness therapy in France, Israel, and the US offer hope to patients and provide a crucial financial lifeline for the company.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

A recent scientific review links low glutathione to brain disease. A new supplement claims to solve the delivery problem. Is this the future of cognitive health?

Artelo Biosciences executes a reverse stock split to fight delisting, but will the financial maneuver be enough to fund its promising drug pipeline?

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

As Galapagos pivots its strategy, it brings in a new HR chief to build the high-performing culture crucial for its next chapter of innovation.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

With a new SVP of Global Sales, Slingshot Biosciences is poised to scale its synthetic cell mimic technology, targeting the booming cell therapy market.

The firm's new ISO 42001 certification signals a major shift towards verifiable, trustworthy AI for the highly regulated life sciences industry.

A new multi-year deal gives RNAi leader Alnylam access to Helix's vast genomic and clinical data, aiming to redefine the speed of drug discovery.